Physician profile
Bill M Smith
NPI 1003881061
$4,747.00
in general payments reported to CMS, 2019-2025
31 companies · $393 in 2025
The $393 reported for 2025 was more than what 80% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.17 · 2020: $11.36 · 2021: $3,338 · 2022: $390 · 2023: $346 · 2024: $191 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,997.12 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $397.24 | 2019-2025 | Euflexxa |
| Novo Nordisk INC | $214.05 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $152.34 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $131.31 | 2021-2025 | |
| Nuvasive, INC. | $97.65 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $97.37 | 2022-2025 | Zilretta, Iovera, Exparel |
| Djo, LLC | $62.69 | 2025 | Cmf |
| Linvatec Corporation | $59.32 | 2022-2023 | Allograft Tissue, Biobrace 23mm |
| Pacira Therapeutics, INC. | $57.14 | 2021 | |
| Amgen INC. | $50.60 | 2021-2024 | Krystexxa, Prolia, Evenity |
| Jazz Pharmaceuticals INC. | $41.57 | 2021 | |
| Seqirus USA INC | $38.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $30.86 | 2022-2025 | Airsupra |
| Avanos Medical | $28.73 | 2023 | Genvisc 850 Sodium Hyaluronate |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $25.25 | 2021-2022 | |
| Fidia Pharma USA INC. | $25.24 | 2022-2023 | Triluron, Hymovis |
| Mallinckrodt Hospital Products INC. | $23.91 | 2024 | Acthar |
| Curonix LLC | $23.71 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Axsome Therapeutics, INC. | $22.24 | 2025 | Auvelity |
| Nevro Corp. | $19.79 | 2023 | Senza |
| Alpha Orthopedic Systems | $19.70 | 2021 | |
| Zimmer Biomet Holdings, INC. | $18.76 | 2021 | |
| Orthofix Medical, INC. | $18.09 | 2025 | Physio-Stim |
| Boston Scientific Corporation | $17.84 | 2021 | |
| Medtronic, INC. | $16.83 | 2023 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $15.22 | 2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $14.78 | 2019 | |
| Smith+Nephew, INC. | $14.69 | 2025 | Pico 14 |
| Bioventus LLC | $14.19 | 2025 | Exogen Ultrasound Bone Healing System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.